Mattias Sandström

Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Ivashchenko, Oleksandra V.; O'Doherty, Jim; Hardiansyah, Deni; Cremonesi, Marta et al.

Ingår i Physica medica (Testo stampato), 2024

• DOI för Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls
• Ladda ner fulltext (pdf) av Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Hindorf, Cecilia; Jessen, Lovisa; Kapidzic, Selma Curkic; Blakkisrud, Johan et al.

Ingår i Physica medica (Testo stampato), 2023

• DOI för Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

Mínguez Gabiña, Pablo; Sjögreen Gleisner, Katarina; Cremonesi, Marta; Stokke, Caroline et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 2595-2604, 2023

• DOI för Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Gear, Jonathan; Stokke, Caroline; Terwinghe, Christelle; Gnesin, Silvano et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1861-1868, 2023

• DOI för EANM enabling guide: how to improve the accessibility of clinical dosimetry
• Ladda ner fulltext (pdf) av EANM enabling guide: how to improve the accessibility of clinical dosimetry

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Jahn, Ulrika; Garske-Román, Ulrike; Sandström, Mattias; Lubberink, Mark et al.

Ingår i EJNMMI Research, s. 45, 2023

• DOI för Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
• Ladda ner fulltext (pdf) av Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Ivashchenko, Oleksandra V.; O'Doherty, Jim; Hardiansyah, Deni; Cremonesi, Marta et al.

Ingår i Physica medica (Testo stampato), 2024

• DOI för Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls
• Ladda ner fulltext (pdf) av Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Hindorf, Cecilia; Jessen, Lovisa; Kapidzic, Selma Curkic; Blakkisrud, Johan et al.

Ingår i Physica medica (Testo stampato), 2023

• DOI för Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

Mínguez Gabiña, Pablo; Sjögreen Gleisner, Katarina; Cremonesi, Marta; Stokke, Caroline et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 2595-2604, 2023

• DOI för Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Gear, Jonathan; Stokke, Caroline; Terwinghe, Christelle; Gnesin, Silvano et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1861-1868, 2023

• DOI för EANM enabling guide: how to improve the accessibility of clinical dosimetry
• Ladda ner fulltext (pdf) av EANM enabling guide: how to improve the accessibility of clinical dosimetry

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Jahn, Ulrika; Garske-Román, Ulrike; Sandström, Mattias; Lubberink, Mark et al.

Ingår i EJNMMI Research, s. 45, 2023

• DOI för Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
• Ladda ner fulltext (pdf) av Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Ingår i Neuroendocrinology, s. 330-343, 2021

• DOI för 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Ladda ner fulltext (pdf) av 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE: Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Lubberink, Mark et al.

Ingår i Cancers, 2021

• DOI för Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE: Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
• Ladda ner fulltext (pdf) av Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE: Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

Bragina, Olga; von Witting, Emma; Garousi, Javad; Zelchan, Roman et al.

Ingår i Journal of Nuclear Medicine, s. 493-499, 2021

• DOI för Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Garske-Román, Ulrike et al.

Ingår i Neuroendocrinology, s. 662-670, 2020

• DOI för ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors

Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE.

Ilan, Ezgi; Velikyan, Irina; Sandström, Mattias; Sundin, Anders et al.

Ingår i Journal of Nuclear Medicine, s. 217-221, 2020

• DOI för Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE.

Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Sandström, Mattias; Freedman, Nanette; Fröss-Baron, Katarzyna; Khan, Tanweera et al.

Ingår i EJNMMI Physics, 2020

• DOI för Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
• Ladda ner fulltext (pdf) av Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Personalized radiation dosimetry for PRRT: how many scans are really required?

Freedman, Nanette; Sandström, Mattias; Kuten, Jonathan; Shtraus, Natan et al.

Ingår i EJNMMI Physics, 2020

• DOI för Personalized radiation dosimetry for PRRT: how many scans are really required?
• Ladda ner fulltext (pdf) av Personalized radiation dosimetry for PRRT: how many scans are really required?

In vivo instability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Lubberink, Mark; Wilking, Helena; Öst, Amalia; Ilan, Ezgi et al.

Ingår i Journal of Nuclear Medicine, s. 1337-1340, 2020

• DOI för In vivo instability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

Vyakaranam, Achyut Ram; Crona, Joakim; Norlén, Olov; Granberg, Dan et al.

Ingår i Cancers, 2019

• DOI för Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.
• Ladda ner fulltext (pdf) av Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3

Vorobyeva, Anzhelika; Schulga, Alexey; Konovalova, Elena; Guler, Rezan et al.

Ingår i Scientific Reports, 2019

• DOI för Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3
• Ladda ner fulltext (pdf) av Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3

Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

Sandström, Mattias; Garske, Ulrike; Johansson, Silvia; Granberg, Dan et al.

Ingår i Acta Oncologica, s. 516-521, 2018

• DOI för Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

In-vivo stability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Wilking, H.; Ilan, Ezgi; Sandström, Mattias; Andersson, C. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI för In-vivo stability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Image contrast of ¹⁷⁷Lu-filled spheres as measured with a GE Discovery 670 CZT SPECT/CT system

Sandström, Mattias; Sundin, Anders; Lubberink, Mark; Ljungberg, M.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI för Image contrast of ¹⁷⁷Lu-filled spheres as measured with a GE Discovery 670 CZT SPECT/CT system

Comparison of Ga-68-DOTATATE and Lu-177-DOTATATE kinetics in neuroendocrine tumors

Ilan, Ezgi; Lubberink, Mark; Sandström, Mattias; Jahn, Ulrika et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

Sandström, Mattias; Fröss-Baron, Katarzyna; Khan, Tanweera Shaheena; Granberg, Dan et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI för Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Garske-Román, Ulrike et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 970-988, 2018

• DOI för Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Ladda ner fulltext (pdf) av Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Ilan, Ezgi; Sandström, Mattias; Velikyan, Irina; Sundin, Anders et al.

Ingår i Journal of Nuclear Medicine, s. 744-749, 2017

• DOI för Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Sjögreen Gleisner, Katarina; Spezi, Emiliano; Solny, Pavel; Minguez Gabina, Pablo et al.

Ingår i EJNMMI Physics, 2017

• DOI för Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
• Ladda ner fulltext (pdf) av Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force

Stokke, Caroline; Gabina, Pablo Minguez; Solny, Pavel; Cicone, Francesco et al.

Ingår i EJNMMI Physics, 2017

• DOI för Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
• Ladda ner fulltext (pdf) av Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force

Low tracer availability of Ga-68-DOTATOC and Ga-68-DOTATATE in blood for patients with high SSTR density leads to non-linear correlation between SUV and K-i

Ilan, Ezgi; Sundin, Anders; Velikyan, Irina; Sandström, Mattias et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

Gender-related differences in absorbed dose to risk organs in patients receiving Lu-177-Octreotate therapy

Sandström, Mattias; Ilan, Ezgi; Fröss-Baron, Katarzyna; Garske, Ulrike et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

Image quality measurements with ¹⁷⁷Lu on a GE Discovery 670 CZT

Sandström, Mattias; Ilan, Ezgi; Sundin, Anders; Lubberink, Mark

Ingår i Journal of Nuclear Medicine, 2017

Is there a gender difference of absorbed dose to the risk organs in patients receiving ¹⁷⁷Lu-Octreotate therapy?

Sandström, Mattias; Ilan, Ezgi; Sundin, Anders; Lubberink, Mark

Ingår i Journal of Nuclear Medicine, 2017

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Sörensen, Jens; Velikyan, Irina; Sandberg, Dan; Wennborg, Anders et al.

Ingår i Theranostics, s. 262-271, 2016

• DOI för Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
• Ladda ner fulltext (pdf) av Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

Honarvar, Hadis; Westerlund, Kristina; Altai, Mohamed; Sandström, Mattias et al.

Ingår i Theranostics, s. 93-103, 2016

• DOI för Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
• Ladda ner fulltext (pdf) av Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases

Ebeling Barbier, Charlotte; Garske-Román, Ulrike; Sandström, Mattias; Nyman, Rickard et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1425-1431, 2016

• DOI för Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases

Comparison of PET/CT and PET/MR-based Ga-68-DOTATOC standardized uptake values

Ilan, Ezgi; Sundin, Anders; Velikyan, Irina; Sandström, Mattias et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2016

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

Sandström, Mattias; Lindskog, Karolina; Velikyan, Irma; Wennborg, Anders et al.

Ingår i Journal of Nuclear Medicine, s. 867-871, 2016

• DOI för Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers

Garousi, Javad; Lindbo, Sarah; Nilvebrant, Johan; Åstrand, Mikael et al.

Ingår i Cancer Research, s. 4364-4371, 2015

• DOI för ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers

Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE

Ilan, Ezgi; Sandström, Mattias; Wassberg, Cecilia; Sundin, Anders et al.

Ingår i Journal of Nuclear Medicine, s. 177-182, 2015

• DOI för Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE

Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.

Sandström, Mattias; Ilan, Ezgi; Karlberg, Anna; Johansson, Silvia et al.

Ingår i EJNMMI Physics, 2015

• DOI för Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.
• Ladda ner fulltext (pdf) av Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.

Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

Mitran, Bogdan; Altai, Mohamed; Hofström, Camilla; Honarvar, Hadis et al.

Ingår i Amino Acids, s. 303-15, 2015

• DOI för Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression
• Ladda ner fulltext (pdf) av Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Andersson, Ken G.; Rosestedt, Maria; Varasteh, Zohreh; Malm, Magdalena et al.

Ingår i Oncology Reports, s. 1042-1048, 2015

• DOI för Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors
• Ladda ner fulltext (pdf) av Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Non-invasive determination of HER2-expression in metastatic breast cancer by using Ga-68-ABY025 PET/CT.

Lindman, Henrik; Wennborg, Anders; Velikyan, Irina; Feldwisch, Joachim et al.

Ingår i Journal of Clinical Oncology, 2015

Accuracy of [Ga-68]ABY-025 PET/CT for determination of HER2-expression in metastatic breast cancer

Sörensen, Jens; Velikyan, Irina; Wennborg, Anders; Feldwisch, Joachim et al.

Ingår i Journal of Nuclear Medicine, 2015

Validation of parametric net influx rate images of Ga-68-DOTATOC and Ga-68-DOTATATE

Ilan, Ezgi; Sandström, Mattias; Velikyan, Irina; Sundin, Anders et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2015

Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors

Ebeling-Barbier, Charlotte; Garske-Roman, Ulrike; Antonodimitrakis, Pantelis; Sandström, Mattias et al.

Ingår i Neuroendocrinology, s. 136-137, 2015

• DOI för Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors

Feasibility of Affibody molecule-based PNA-mediated pretargeting

Honarvar, Hadis; Westerlund, K.; Altai, Mohamed; Sandstrom, Mattias et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2015

Fractional contribution of extrapolations after 96 h in absorbed dose calculation to kidneys in 450 patients with neuroendocrine tumours receiving Lu-177-DOTATATE therapy

Sandström, Mattias; Garske-Roman, Ulrike; Granberg, Dan; Sundin, Anders et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2015

Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting: proof-of-principle

Altai, Mohamed; Tsourma, M.; Mitran, Bogdan; Honarvar, Hadis et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2015

111In-labeled NOTA-conjugated Affibody molecules for visualization of HER3 expression in malignant tumors

Andersson, K. G.; Varasteh, Zohreh; Rosestedt, Maria; Malm, M. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination: first-in-man

Velikyan, Irina; Wennborg, A.; Feldwisch, J.; Orlova, Anna et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

Development of ADAPT6 as a new scaffold protein for radionuclide molecular imaging

Garousi, Javad; Lindbo, S.; Orlova, Anna; Astrand, M. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

Radiation dosimetry and tracer kinetic analysis of Ga-68-ABY025 Affibody in breast cancer patients

Lubberink, Mark; Lindskog, K.; Sandström, Mattias; Velikyan, Irina et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

Favourable outcome after 177Lu-DOTA-octreotate therapy of patients with neuroendocrine of the rectum -an update

Garske-Roman, Ulrike E.; Sandström, Mattias; Johansson, Silvia; Fröss-Baron, Katarzyna et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT

Sörensen, Jens; Velikyan, Irina; Wennborg, A.; Feldwisch, J. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

Comparison of [68Ga]-DOTA-TOC and [68Ga]-DOTA-TATE: Aspects on quantification in neuroendocrine tumour therapy monitoring

Sundin, Anders; Velikyan, Irina; Sörensen, Jens; Garske-Roman, Ulrike et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2014

¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment

Altai, Mohamed; Wållberg, Helena; Honarvar, Hadis; Strand, Joanna et al.

Ingår i Journal of Nuclear Medicine, s. 1842-1848, 2014

• DOI för ¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment
• Ladda ner fulltext (pdf) av ¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Velikyan, Irina; Sundin, Anders; Sörensen, Jens; Lubberink, Mark et al.

Ingår i Journal of Nuclear Medicine, s. 204-10, 2014

• DOI för Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re

Altai, Mohamed; Honarvar, Hadis; Wållberg, Helena; Strand, Joanna et al.

Ingår i European Journal of Medicinal Chemistry, s. 519-528, 2014

• DOI för Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re
• Ladda ner fulltext (pdf) av Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule

Sörensen, Jens; Sandberg, Dan; Sandström, Mattias; Wennborg, Anders et al.

Ingår i Journal of Nuclear Medicine, s. 730-735, 2014

• DOI för First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule
• Ladda ner fulltext (pdf) av First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Sandström, Mattias; Garske-Román, Ulrike; Granberg, Dan; Johansson, Silvia et al.

Ingår i Journal of Nuclear Medicine, s. 33-41, 2013

• DOI för Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

[^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

Orlova, Anna; Hofström, Camilla; Strand, Joanna; Varasteh, Zohreh et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 439-449, 2013

• DOI för [^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours
• Ladda ner fulltext (pdf) av [^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

Varasteh, Zohreh; Åberg, Ola; Velikyan, Irina; Lindeberg, Gunnar et al.

Ingår i PLOS ONE, 2013

• DOI för In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
• Ladda ner fulltext (pdf) av In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging

Varasteh, Zohreh; Velikyan, Irina; Lindeberg, Gunnar; Sörensen, Jens et al.

Ingår i Bioconjugate chemistry, s. 1144-1153, 2013

• DOI för Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging
• Ladda ner fulltext (pdf) av Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging

Comparison of radiation dosimetry of [Ga-68]Ga-DOTA-TOC and [Ga-68]Ga-DOTA-TATE in patients affected by neuroendocrine tumours

Velikyan, Irina; Sandström, Mattias; Garske, Ulrike; Sörensen, Jens et al.

Ingår i Journal of labelled compounds & radiopharmaceuticals, 2013

Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

Sandström, Mattias; Velikyan, Irina; Garske-Roman, Ulrike; Sörensen, Jens et al.

Ingår i Journal of Nuclear Medicine, s. 1755-1759, 2013

• DOI för Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

GRPR antagonist NOTA-P2-RM26 labeled with fluorine-18: radiochemistry, in vitro and in vivo evaluation

Varasteh, Zohreh; Åberg, Ola; Lindberg, G.; Antoni, Gunnar et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2013

Biological effective doses in 300 patients undergoing therapy with Lu-177-octreotate

Sandström, Mattias; Garske-Roman, Ulrike; Granberg, Dan; Eriksson, B. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2013

Selection of an optimal cysteine-containing peptide-based chelator for labeling of Affibody molecules with 188-Re

Altai, Mohamed; Honarvar, Hadis; Wållberg, Helena; Strand, Joanna et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2013

• DOI för Selection of an optimal cysteine-containing peptide-based chelator for labeling of Affibody molecules with 188-Re

Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Granberg, Dan et al.

Ingår i Theranostics, s. 459-471, 2012

• DOI för Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹In using a maleimido derivative of NODAGA

Altai, Mohamed; Perols, Anna; Eriksson Karlström, Amelie; Sandström, Mattias et al.

Ingår i Nuclear Medicine and Biology, s. 518-529, 2012

• DOI för Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹In using a maleimido derivative of NODAGA

Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging

Rosik, Daniel; Orlova, Anna; Malmberg, Jennie; Altai, Mohamed et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 693-702, 2012

• DOI för Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Malmberg, Jennie; Perols, Anna; Varasteh, Zohreh; Altai, Mohamed et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 481-492, 2012

• DOI för Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_IGF1R:4551

Tolmachev, Vladimir; Malmberg, Jennie; Hofström, Camilla; Abrahmsén, Lars et al.

Ingår i Journal of Nuclear Medicine, s. 90-97, 2012

• DOI för Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_IGF1R:4551

Regional Lung Perfusion estimated by Electrical Impedance Tomography in a piglet model of lung collapse

Borges, João Batista; Suarez-Sipmann, Fernando; Bohm, Stephan H; Tusman, Gerardo et al.

Ingår i Journal of applied physiology, s. 225-236, 2011

• DOI för Regional Lung Perfusion estimated by Electrical Impedance Tomography in a piglet model of lung collapse

Ventilation Distribution Studies Comparing Technegas and "Gallgas" Using (GaCl3)-Ga-68 as the Label

Borges, João Batista; Velikyan, Irina; Långström, Bengt; Sörensen, Jens et al.

Ingår i Journal of Nuclear Medicine, s. 206-209, 2011

• DOI för Ventilation Distribution Studies Comparing Technegas and "Gallgas" Using (GaCl3)-Ga-68 as the Label

Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate

Tolmachev, Vladimir; Feldwisch, Joachim; Lindborg, Malin; Baastrup, Barbro et al.

Ingår i Nuclear Medicine and Biology, s. 697-706, 2011

• DOI för Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate

Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules

Tolmachev, Vladimir; Altai, Mohamed; Sandström, Mattias; Perols, Anna et al.

Ingår i Bioconjugate chemistry, s. 894-902, 2011

• DOI för Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

Tolmachev, Vladimir; Wållberg, Helena; Sandström, Mattias; Hansson, Monika et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 531-539, 2011

• DOI för Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Sundin, Anders et al.

Ingår i Acta Oncologica, s. 86-96, 2011

• DOI för Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on (111)In- and (125)I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody

Malmberg, Jennie; Sandström, Mattias; Wester, Kenneth; Tolmachev, Vladimir et al.

Ingår i Nuclear Medicine and Biology, s. 1093-1102, 2011

• DOI för Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on (111)In- and (125)I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody

Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

Ahlgren, Sara; Orlova, Anna; Wållberg, Helena; Hansson, Monika et al.

Ingår i Journal of Nuclear Medicine, s. 1131-1138, 2010

• DOI för Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

A HER2-binding Affibody molecule labelled with ⁶⁸Ga for PET imaging: direct in vivo comparison with the ¹¹¹In-labelled analogue

Tolmachev, Vladimir; Velikyan, Irina; Sandström, Mattias; Orlova, Anna

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1356-1367, 2010

• DOI för A HER2-binding Affibody molecule labelled with ⁶⁸Ga for PET imaging: direct in vivo comparison with the ¹¹¹In-labelled analogue

Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Sandström, Mattias; Garske, Ulrike; Granberg, Dan; Sundin, Anders et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 212-225, 2010

• DOI för Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

Tolmachev, Vladimir; Friedman, Mikaela; Sandström, Mattias; Eriksson, Tove L. et al.

Ingår i Journal of Nuclear Medicine, s. 274-283, 2009

• DOI för Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Tolmachev, Vladimir; Orlova, Anna; Pehrson, Rikard; Galli, Joakim et al.

Ingår i Cancer Research, s. 2773-2782, 2007

• DOI för Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

Orlova, Anna; Tolmachev, Vladimir; Pehrson, Rikard; Lindborg, Malin et al.

Ingår i Cancer Research, s. 2178-2186, 2007

• DOI för Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand

Tran, Thuy; Orlova, Anna; Sivaev, Igor; Sandström, Mattias et al.

Ingår i International Journal of Molecular Medicine, s. 485-493, 2007

Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM.

Razifar, Pasha; Sandström, Mattias; Schneider, Harald; Långström, Bengt et al.

Ingår i Bio Medical Central (BMC): Medical Imaging, 2005

• DOI för Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM.

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Persson, Mikael; Tolmachev, Vladimir; Andersson, Karl; Gedda, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1457-62, 2005

• DOI för [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

Sandström, Mattias; Tolmachev, Vladimir; Kairemo, Kalevi; Lundqvist, Hans et al.

Ingår i Physics in Medicine and Biology, s. 5419-32, 2004

• DOI för Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

Comparison of ⁶⁸Ga-DOTATATE and ¹⁷⁷Lu-DOTATATE kinetics in neuroendocrine tumors

Ilan, Ezgi; Velikyan, Irina; Sandström, Mattias; Andersson, Camilla et al.

Dosimetry of Radionuclide Therapy with ¹⁷⁷Lu-octreotate

Sandström, Mattias

2011

• Ladda ner fulltext (pdf) av Dosimetry of Radionuclide Therapy with ¹⁷⁷Lu-octreotate